Kodiak Sciences Inc (OQ:KOD)

Sector:  Healthcare Industry:  Biotechnology & Medical Research
 
See Regulatory Filings on SEC
Company Contact
Address: 1200 PAGE MILL RD
PALO ALTO CA 94304
Tel: N/A
Website: https://kodiak.com
IR: See website
<
Key People
Victor Perlroth
Chairman of the Board, President, Chief Executive Officer, Co-Founder
John A. Borgeson
Chief Financial Officer, Executive Vice President, Secretary
 
Business Overview
Kodiak Sciences Inc. is a biopharmaceutical company. The Company has developed a new technology platform, the Antibody Biopolymer Conjugate (ABC) Platform, for retinal medicines. Its ABC Platform uses molecular engineering to merge the fields of protein-based and chemistry-based therapies. Its lead investigational medicine, tarcocimab, is a novel anti-vascular endothelial growth factor (anti-VEGF) antibody biopolymer conjugate under development for the treatment of high prevalence retinal vascular diseases, including diabetic retinopathy, the cause of blindness in working-age patients in the developed world, and wet age-related macular degeneration, the cause of blindness in elderly patients. Its second investigational medicine, KSI-501, is a bispecific antibody biopolymer conjugate targeting the pro-inflammatory cytokine interleukin-6 (IL-6) and VEGF. It is also developing a third investigational medicine, KSI-101, an unconjugated bispecific protein targeting IL-6 and VEGF.
Financial Overview
For the fiscal year ended 31 December 2023, Kodiak Sciences Inc revenues was not reported. Net loss decreased 22% to $260.5M. Lower net loss reflects Research and development decrease of 22% to $162.3M (expense), Stock-based Compensation in R&D decrease of 26% to $44M (expense), Interest income increase from $7.1M to $16.7M (income). Basic Earnings per Share excluding Extraordinary Items increased from -$6.39 to -$4.97.
Employees: 111 as of Dec 31, 2023
Reporting Currency: U.S. Dollars
Enterprise value: N/A
Annual revenue (TTM): $0.00M as of Dec 31, 2023
EBITDA (TTM): -$259.02M as of Dec 31, 2023
Net annual income (TTM): -$260.49M as of Dec 31, 2023
Free cash flow (TTM): -$195.61M as of Dec 31, 2023
Net Debt Last Fiscal Year: N/A
Shares outstanding: 52,508,602 as of Feb 29, 2024
TTM: Trailing Twelve Months
EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization

Thank you for visiting InsiderTracking.com. We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you wish to consider using a browser that blocks ads, please log in or subscribe.

Alternatively, if you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). If you are in private browsing mode and do not want to subscribe, please disable tracking protection while visiting our website.

Thank you for using Insider Tracking.